By SectorWire desk ·
The report said that Kalshi introduced contracts related to medicine trials and regulatory decisions. The US offering includes contracts on drug approvals involving Sanofi and Gilead Sciences.
The products extend Kalshi’s event contracts into biotechnology and medicine regulation.
Request a correction / right of reply
Linked through shared companies, regulators and people, or one step further through the graph.
The dispute concerns whether states can apply gambling rules to sports-event contracts offered by federally regulated exchanges.
The findings bear on state challenges to Kalshi and Polymarket's position that their contracts fall exclusively under CFTC jurisdiction.
The analysis questions Kalshi’s explanation for concentrated activity in its ether perpetual contracts.
The new contracts allow partial settlement rather than requiring players to reach the full statistical target.
The dispute could affect whether prediction market operators face state gambling laws alongside federal oversight.
The denial challenges Kalshi’s account of a tribal partnership.